Pediatrix Medical Group (NYSE:MD) Shares Pass Above 200 Day Moving Average – Should You Sell?

Pediatrix Medical Group, Inc. (NYSE:MD) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $18.37 and traded as high as $22.47. Pediatrix Medical Group shares last traded at $22.24, with a volume of 450,218 shares trading hands.

Analysts Set New Price Targets

MD has been the subject of a number of research reports. Zacks Research raised shares of Pediatrix Medical Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 21st. UBS Group boosted their price target on shares of Pediatrix Medical Group from $16.50 to $23.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Wall Street Zen raised Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 4th. Truist Financial lifted their price objective on Pediatrix Medical Group from $17.00 to $24.00 and gave the stock a “hold” rating in a report on Monday, November 10th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Pediatrix Medical Group Stock Performance

The company has a market capitalization of $1.85 billion, a PE ratio of 11.31 and a beta of 0.73. The company has a 50 day moving average of $22.39 and a two-hundred day moving average of $18.42. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.83 and a quick ratio of 1.83.

Pediatrix Medical Group (NYSE:MD) last announced its earnings results on Monday, November 3rd. The company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.21. Pediatrix Medical Group had a net margin of 8.44% and a return on equity of 20.45%. The business had revenue of $492.88 million during the quarter, compared to the consensus estimate of $476.45 million. During the same quarter last year, the firm earned $0.44 earnings per share. The business’s revenue for the quarter was down 3.6% on a year-over-year basis. As a group, equities research analysts predict that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current year.

Insider Transactions at Pediatrix Medical Group

In related news, Director Laura A. Linynsky sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $21.65, for a total transaction of $216,500.00. Following the completion of the sale, the director owned 32,232 shares of the company’s stock, valued at $697,822.80. This trade represents a 23.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Mark S. Ordan sold 23,000 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $22.41, for a total value of $515,430.00. Following the completion of the transaction, the chief executive officer directly owned 302,805 shares in the company, valued at $6,785,860.05. This trade represents a 7.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 43,478 shares of company stock worth $972,924. Corporate insiders own 0.90% of the company’s stock.

Institutional Trading of Pediatrix Medical Group

Large investors have recently modified their holdings of the company. Smartleaf Asset Management LLC lifted its holdings in Pediatrix Medical Group by 10.6% in the third quarter. Smartleaf Asset Management LLC now owns 6,250 shares of the company’s stock valued at $101,000 after acquiring an additional 601 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Pediatrix Medical Group by 4.5% during the third quarter. PNC Financial Services Group Inc. now owns 14,525 shares of the company’s stock valued at $243,000 after purchasing an additional 631 shares in the last quarter. Gotham Asset Management LLC raised its holdings in Pediatrix Medical Group by 0.6% during the third quarter. Gotham Asset Management LLC now owns 116,093 shares of the company’s stock valued at $1,945,000 after acquiring an additional 724 shares during the period. Amalgamated Bank raised its stake in Pediatrix Medical Group by 3.5% during the 3rd quarter. Amalgamated Bank now owns 24,891 shares of the company’s stock valued at $417,000 after purchasing an additional 831 shares during the period. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its stake in Pediatrix Medical Group by 8.7% during the second quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 11,913 shares of the company’s stock valued at $171,000 after acquiring an additional 950 shares in the last quarter. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.